Comparative effects of pirfenidone and nintedanib in experimental intraabdominal adhesion model.

IF 1.1 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY
Olgun Erdem, Selin Karaman Erdem, Abdullah Yıldız, Hakan Çakıt, Ceren Canbey, Ömer Faruk Özkan
{"title":"Comparative effects of pirfenidone and nintedanib in experimental intraabdominal adhesion model.","authors":"Olgun Erdem, Selin Karaman Erdem, Abdullah Yıldız, Hakan Çakıt, Ceren Canbey, Ömer Faruk Özkan","doi":"10.1016/j.ajg.2025.07.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Postoperative peritoneal adhesions (PPA) develop in up to 90% of intraabdominal surgeries and are a major cause of small bowel obstruction, leading to readmissions and morbidity. However, no effective pharmacologic strategy currently exists for PPA prevention. Pirfenidone and Nintedanib are oral antifibrotics approved for idiopathic pulmonary fibrosis, with emerging data on their effects in cardiac and hepatic fibrosis. This study aimed to compare their efficacy in preventing PPA via intraperitoneal (IP) administration in an experimental model.</p><p><strong>Methods: </strong>Twenty-eight rats were randomized into four groups of 7: Pirfenidone (P), Nintedanib (N), combination (P + N), and saline control (C). Adhesions were induced via cecal abrasion. On postoperative day 7, macroscopic fibrosis scores (MFS), affected regions, histopathology, and TGF-β1 expression were evaluated.</p><p><strong>Results: </strong>Group P had significantly lower MFS than Group N (P < 0.001) and showed a reduction trend vs. control. TGF-β1 HScore was significantly lower in Group P vs. Group N (P = 0.002) and P + N (P = 0.014). Group N showed the highest inflammation and elevated TGF-β1 vs. control (P = 0.013).</p><p><strong>Conclusion: </strong>Pirfenidone appears effective in reducing PPA formation via IP administration. In contrast, Nintedanib may be unsuitable for IP use in saline, potentially due to poor solubility.</p>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arab Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajg.2025.07.002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Postoperative peritoneal adhesions (PPA) develop in up to 90% of intraabdominal surgeries and are a major cause of small bowel obstruction, leading to readmissions and morbidity. However, no effective pharmacologic strategy currently exists for PPA prevention. Pirfenidone and Nintedanib are oral antifibrotics approved for idiopathic pulmonary fibrosis, with emerging data on their effects in cardiac and hepatic fibrosis. This study aimed to compare their efficacy in preventing PPA via intraperitoneal (IP) administration in an experimental model.

Methods: Twenty-eight rats were randomized into four groups of 7: Pirfenidone (P), Nintedanib (N), combination (P + N), and saline control (C). Adhesions were induced via cecal abrasion. On postoperative day 7, macroscopic fibrosis scores (MFS), affected regions, histopathology, and TGF-β1 expression were evaluated.

Results: Group P had significantly lower MFS than Group N (P < 0.001) and showed a reduction trend vs. control. TGF-β1 HScore was significantly lower in Group P vs. Group N (P = 0.002) and P + N (P = 0.014). Group N showed the highest inflammation and elevated TGF-β1 vs. control (P = 0.013).

Conclusion: Pirfenidone appears effective in reducing PPA formation via IP administration. In contrast, Nintedanib may be unsuitable for IP use in saline, potentially due to poor solubility.

吡非尼酮与尼达尼布对实验性腹腔粘连模型的影响比较。
背景:术后腹膜粘连(PPA)在高达90%的腹内手术中发生,是小肠梗阻的主要原因,导致再入院和发病率。然而,目前尚无有效的药理学策略来预防PPA。吡非尼酮和尼达尼布是批准用于特发性肺纤维化的口服抗纤维化药物,其在心脏和肝纤维化中的作用正在出现新的数据。本研究的目的是在实验模型中比较它们通过腹腔注射(IP)预防PPA的功效。方法:将28只大鼠随机分为吡非尼酮(P)、尼达尼布(N)、联合用药(P + N)和生理盐水对照组(C) 4组,每组7只。通过盲肠磨损诱导粘连。术后第7天观察宏观纤维化评分(MFS)、影响区域、组织病理学及TGF-β1表达情况。结果:P组患者MFS明显低于N组。结论:吡非尼酮通过给药可有效减少PPA的形成。相反,尼达尼布可能不适合在生理盐水中使用IP,可能是由于溶解性差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Arab Journal of Gastroenterology
Arab Journal of Gastroenterology Medicine-Gastroenterology
CiteScore
2.70
自引率
0.00%
发文量
52
期刊介绍: Arab Journal of Gastroenterology (AJG) publishes different studies related to the digestive system. It aims to be the foremost scientific peer reviewed journal encompassing diverse studies related to the digestive system and its disorders, and serving the Pan-Arab and wider community working on gastrointestinal disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信